title: Evidence on the identity of the CXCR2 antagonist AZD-5069.
abstract: Crystalline forms A and D of N-[2-[[(2,3-difluoropheny)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide are claimed. The compound is a previously disclosed CXCR2 chemokine receptor antagonist and is claimed to be useful in the treatment of inflammatory diseases such as chronic obstructive pulmonary disease (COPD).
authors.affiliation: Norman Consulting, Burnham, Bucks, UK. peter.norman2@btinternet.com
authors.forename: Peter
authors.initials: P
authors.lastname: Norman
mesh_terms: D000818:Animals; D003460:Crystallization; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D010330:Patents as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000473:pathology; D023063:Receptors, Interleukin-8B / Q000037:antagonists & inhibitors*
chemical_list: D023063:Receptors, Interleukin-8B